Skip to main content

Table 3 The common TRAEs of rezivertinib in SS

From: Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study

 

Any grade, n (%)

Grade ≥ 3, n (%)

WBC decreased

19 (44.2)

0

PLT decreased

17 (39.5)

1 (2.3)

ANC decreased

13 (30.2)

0

Anemia

11 (25.6)

1 (2.3)

ALT increased

8 (18.6)

0

Lymphocyte count decreased

6 (14.0)

1 (2.3)

AST increased

5 (11.6)

0

Leukopenia

4 (9.3)

1 (2.3)

Drug eruption

4 (9.3)

0

Rash

3 (7.0)

0

Thrombocytopenia

3 (7.0)

0

Hypertriglyceridemia

3 (7.0)

0

  1. CTCAE version 4.03, MedDRA version 24.1. Data are indicated as n (%). Any grade TRAEs of 5% or higher and grade 3–5 TRAEs of 1% or higher are reported
  2. Abbreviations: TRAEs Treatment-related adverse events, SS Safety set, WBC White blood cell, PLT Platelet, ANC Absolute neutrophil count, ALT Alanine aminotransferase, AST Aspartate aminotransferase, CTCAE Common Terminology Criteria for Adverse Events, MedDRA Medical Dictionary for Regulatory Activities